The interplay between PP2A and microRNAs in leukemia

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Ruvolo, Peter P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AKT; Leukemia; microRNA; PP2A; Signal transduction

Indexed keywords

MICRORNA; MICRORNA 155; MICRORNA 19; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN P53; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL SURVIVAL; GENE OVEREXPRESSION; GENETIC REGULATION; HOMEOSTASIS; HUMAN; LEUKEMIA; ONCOGENE MYC; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 84923567495     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00043     Document Type: Review

References (109)

1. Janssens V, Longin S, Goris J. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci (2008) 33:113-21. doi: 10.1016/j.tibs.2007.12.004
2. Janssens V, Rebollo A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med (2012) 12:268-87. doi:10.2174/156652412799218930
3. Mumby MC, Walter G. Protein serine/threonine phosphatases: structure, regulation, and function in cell growth. Physiol Rev (1993) 73:673-99.
4. Orgad S, Brewis ND, Alphey L, Dudai Y, Cohen PT. The structure of protein phosphatase 2A is as highly conserved as that of protein phosphatase 1. FEBS Lett (1990) 275:44-8. doi:10.1016/0014-5793(90)81435-Q
5. McCright B, Virshup DM. Identification of a new family of protein phosphatase 2A regulatory subunits. J Biol Chem (1995) 270:26123-8. doi:10.1074/jbc.270.44.26123
6. Stone SR, Hofsteenge J, Hemmings BA. Molecular cloning of cDNAs encoding two isoforms of the catalytic subunit of protein phosphatase 2A. Biochemistry (1987) 26:7215-20. doi:10.1021/bi00397a003
7. Hemmings BA, Adams-Pearson C, Maurer F, Muller P, Goris J, Merlevede W, et al. Alpha and beta forms of the 65kd subunit of protein phosphatase 2A have similar 39 amino acid repeating structure. Biochemistry (1990) 29:3166-73. doi:10.1021/bi00465a002
8. Silverstein AM, Barrow CA, Davis AJ, Mumby MC. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci U S A (2002) 99:4221-6. doi:10.1073/pnas.072071699
9. Strack S, Cribbs JT, Gomez L. Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival. J Biol Chem (2004) 279:47732-9. doi:10.1074/jbc.M408015200
10. Ruvolo VR, Kurinna SM, Karanjeet KB, Schuster TF, Martelli AM, McCubrey JA, et al. PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem (2008) 283:35474-85. doi:10.1074/jbc.M800951200
11. Chen J, Parsons S, Brautigan DL. Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. J Biol Chem (1994) 269:7957-62.
12. Vacaru AM, den Hertog J. Serine dephosphorylation of receptor protein tyrosine phosphatase alpha in mitosis induces Src binding and activation. Mol Cell Biol (2010) 30:2850-61. doi:10.1128/MCB.01202-09
13. Tolstykh T, Lee J, Vafai S, Stock JB. Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits. EMBO J (2000) 19:5682-91. doi:10.1093/emboj/19.21.5682
14. Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, Brautigan DL, et al. Polyoma small and middle T antigens and SV40 small T antigen form stable complexes with protein phosphatase 2A. Cell (1990) 60:167-76. doi:10.1016/0092-8674(90)90726-U
15. Yang SI, Lickteig RL, Estes R, Rundell K, Walter G, Mumby MC. Control of protein phosphatase 2A by simian virus 40 small-T antigen. Mol Cell Biol (1991) 11:1988-95.
16. Mateer SC, Fedorov SA, Mumby MC. Identification of structural elements involved in the interaction of simian virus 40 small tumor antigen with protein phosphatase 2A. J Biol Chem (1998) 273:35339-46. doi:10.1074/jbc.273.52.35339
17. Mullane KP, Ratnofsky M, Cullere X, Schaffhausen B. Signaling from polyomavirus middle T and small T defines different roles for protein phosphatase 2A. Mol Cell Biol (1998) 18:7556-64.
18. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 8:355-68. doi:10.1016/j.ccr.2005.10.015
19. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer (2006) 95:775-81. doi:10.1038/sj.bjc.6603317
20. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 117:2408-21. doi:10.1172/JCI31095
21. Yang Y, Huang Q, Lu Y, Li X, Huang S. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem (2012) 113:1314-22. doi:10.1002/jcb.24003
22. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev (2008) 27:159-68. doi:10.1007/s10555-008-9119-x
23. Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol (2013) 14:e229-38. doi:10.1016/S1470-2045(12)70558-2
24. Calin GA, di Iasio MG, Caprini E, Vorechovsky I, Natali PG, Sozzi G, et al. Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene (2000) 19:1191-5. doi:10.1038/sj.onc.1203389
25. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science (1998) 282:284-7. doi:10.1126/science.282.5387.284
26. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A (2009) 106:12974-9. doi:10.1073/pnas.0811267106
27. Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A, MacBeth KJ. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann Hematol (2014) 93:1-11. doi:10.1007/s00277-013-1863-5
28. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 108:2358-65. doi:10.1182/blood-2006-02-003475
29. Scholl C, Gilliland DG, Fröhling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol (2008) 35:336-45. doi:10.1053/j.seminoncol.2008.04.004
30. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1:89-103.
31. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades. Oncotarget (2012) 3:954-87.
32. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 150:264-78. doi:10.1016/j.cell.2012.06.023
33. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, et al. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia (2009) 23:1029-38. doi:10.1038/leu.2008.395
34. Cristóbal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood (2010) 115:615-25. doi:10.1182/blood-2009-06-227363
35. Cristóbal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia (2011) 25:606-14. doi:10.1038/leu.2010.294
36. Cristóbal I, Cirauqui C, Castello-Cros R, Garcia-Orti L, Calasanz MJ, Odero MD. Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells. Haematologica (2013) 98:e103-14. doi:10.3324/haematol.2013.084731
37. Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, et al. Low expression of PP2A regulatory subunit B55alpha is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia (2011) 25:1711-7. doi:10.1038/leu.2011.146
38. Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, et al. The protein phosphatase 2A regulatory subunit B55a is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta (2014) 1843:1969-77. doi:10.1016/j.bbamcr.2014.05.006
39. Hales EC, Orr SM, Larson Gedman A, Taub JW, Matherly LH. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. J Biol Chem (2013) 288:22836-48. doi:10.1074/jbc.M113.451625
40. Blalock WL, Grimaldi C, Fala F, Follo M, Horn S, Basecke J, et al. PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. J Cell Physiol (2009) 221:232-41. doi:10.1002/jcp.21848
41. Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest (2014) 124:644-55. doi:10.1172/JCI65093
42. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 75:843-54. doi:10.1016/0092-8674(93)90529-Y
43. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 99:15524-9. doi:10.1073/pnas.242606799
44. Kunej T, Godnic I, Horvat S, Zorc M, Calin GA. Cross talk between microRNA and coding cancer genes. Cancer J (2012) 18:223-31. doi:10.1097/PPO.0b013e318258b771
45. Van Roosbroeck K, Pollet J, Calin GA. miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn (2013) 13:183-204. doi:10.1586/erm.12.134
46. Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks. J Mol Biol (2013) 425:3582-600. doi:10.1016/j.jmb.2013.03.007
47. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2008) 40:43-50. doi:10.1038/ng.2007.30
48. Copley MR, Eaves CJ. Developmental changes in hematopoietic stem cell properties. Exp Mol Med (2013) 45:e55. doi:10.1038/emm.2013.98
49. Shyh-Chang N, Daley GQ. Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell (2013) 12:395-406. doi:10.1016/j.stem.2013.03.005
50. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest (2013) 123:2395-407. doi:10.1172/JCI66553
51. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene (2006) 25:6202-10. doi:10.1038/sj.onc.1209910
52. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med (2006) 12:580-7. doi:10.1016/j.molmed.2006.10.006
53. Marcucci G, Radmacher MD, Mrozek K, Bloomfield CD. MicroRNA expression in acute myeloid leukemia. Curr Hematol Malig Rep (2009) 4:83-8. doi:10.1007/s11899-009-0012-7
54. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ (2010) 17:215-20. doi:10.1038/cdd.2009.69
55. Calin GA, Pekarsky Y, Croce CM. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol (2007) 20:425-37. doi:10.1016/j.beha.2007.02.003
56. Wang Y, Li Z, He C, Wang D, Yuan X, Chen J, et al. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis (2010) 44:191-7. doi:10.1016/j.bcmd.2009.12.010
57. Barbarotto E, Calin GA. Potential therapeutic applications of miRNA-based technology in hematological malignancies. Curr Pharm Des (2008) 14:2040-50. doi:10.2174/138161208785294627
58. Pons A, Nomdedeu B, Navarro A, Gaya A, Gel B, Diaz T, et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma (2009) 50:1854-9. doi:10.3109/10428190903147645
59. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A (2009) 106:7113-8. doi:10.1073/pnas.0902636106
60. Rokah OH, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One (2012) 7:e35501. doi:10.1371/journal.pone.0035501
61. Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrózek K, Becker H, et al. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia (2013) 27:2023-31. doi:10.1038/leu.2013.181
62. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol (2013) 31:2086-93. doi:10.1200/JCO.2012.45.6228
63. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood (2014) 124:546-54. doi:10.1182/blood-2014-03-559690
64. Li X, Zhang J, Gao L, McClellan S, Finan MA, Butler TW, et al. miR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death Differ (2012) 19:378-86. doi:10.1038/cdd.2011.127
65. Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood (2012) 119:2314-24. doi:10.1182/blood-2011-10-386235
66. Chen HG, Han WJ, Deng M, Qin J, Yuan D, Liu JP, et al. Transcriptional regulation of PP2A-A alpha is mediated by multiple factors including AP-2alpha, CREB, ETS-1, and SP-1. PLoS One (2009) 4:e7019. doi:10.1371/journal.pone.0007019
67. Chen HF, Mai JR, Wan JX, Gao YF, Lin LN, Wang SZ, et al. Role of a novel functional variant in the PPP2R1A promoter on the regulation of PP2A-Aalpha and the risk of hepatocellular carcinoma. PLoS One (2013) 8:e59574. doi:10.1371/journal.pone.0059574
68. Nagpal K, Watanabe KS, Tsao BP, Tsokos GC. Transcription factor Ikaros represses protein phosphatase 2A (PP2A) expression through an intronic binding site. J Biol Chem (2014) 289:13751-7. doi:10.1074/jbc.M114.558197
69. Su JL, Chen PB, Chen YH, Chen SC, Chang YW, Jan YH, et al. Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. Cancer Res (2010) 70:5096-108. doi:10.1158/0008-5472.CAN-09-4148
70. Yu YH, Chen HA, Chen PS, Cheng YJ, Hsu WH, Chang YW, et al. miR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene (2013) 32:431-43. doi:10.1038/onc.2012.74
71. Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon JH, et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res (2011) 17:3029-38. doi:10.1158/1078-0432.CCR-10-2532
72. Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, et al. miR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res (2010) 16:867-75. doi:10.1158/1078-0432.CCR-09-1840
73. Zhang Y, Ma T, Yang S, Xia M, Xu J, An H, et al. High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. Mol Cell Biochem (2011) 357:363-71. doi:10.1007/s11010-011-0907-1
74. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 120:1298-309. doi:10.1172/JCI39566
75. Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM, et al. MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One (2011) 6:e28324. doi:10.1371/journal.pone.0028324
76. Holla S, Kurowska-Stolarska M, Bayry J, Balaji KN. Selective inhibition of IFNG-induced autophagy by miR155- and miR31-responsive WNT5A and SHH signaling. Autophagy (2014) 10:311-30. doi:10.4161/auto.27225
77. Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol (2010) 12:372-9. doi:10.1038/ncb2037
78. Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of ?-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal (2014) 26:149-61. doi:10.1016/j.cellsig.2013.09.021
79. Liu X, Liu Q, Fan Y, Wang S, Liu X, Zhu L, et al. Downregulation of PPP2R5E expression by miR-23a suppresses apoptosis to facilitate the growth of gastric cancer cells. FEBS Lett (2014) 588:3160-9. doi:10.1016/j.febslet.2014.05.068
80. Suzuki HI, Matsuyama H, Noguchi M, Yao T, Komatsu N, Mano H, et al. Computational dissection of distinct microRNA activity signatures associated with peripheral T cell lymphoma subtypes. Leukemia (2013) 27:2107-11. doi:10.1038/leu.2013.121
81. Chao A, Tsai CL, Wei PC, Hsueh S, Chao AS, Wang CJ, et al. Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett (2010) 291:99-107. doi:10.1016/j.canlet.2009.10.005
82. Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, et al. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell (2013) 24(1638-1648):S1-7. doi:10.1091/mbc.E12-12-0891
83. Wang XS, Gong JN, Yu J, Wang F, Zhang XH, Tan ZQ, et al. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood (2012) 119:4992-5004. doi:10.1182/blood-2011-10-385716
84. Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y, et al. Induction of microRNAs, miR-155, miR-222, miR-424 and miR-503, promotes monocytic differentiation through combinatorial regulation. Leukemia (2010) 24:460-6. doi:10.1038/leu.2009.246
85. Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 103:5078-83. doi:10.1073/pnas.0600587103
86. Undi RB, Kandi R, Gutti RK. MicroRNAs as haematopoiesis regulators. Adv Hematol (2013) 2013:695754. doi:10.1155/2013/695754
87. Ferracin M, Zagatti B, Rizzotto L, Cavazzini F, Veronese A, Ciccone M, et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer (2010) 9:123. doi:10.1186/1476-4598-9-123
88. Nobumori Y, Shouse GP, Wu Y, Lee KJ, Shen B, Liu X. B56? tumor-associated mutations provide new mechanisms for B56?-PP2A tumor suppressor activity. Mol Cancer Res (2013) 11:995-1003. doi:10.1158/1541-7786.MCR-12-0633
89. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 111:3183-9. doi:10.1182/blood-2007-07-098749
90. Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol (2006) 26:2832-44. doi:10.1128/MCB.26.7.2832-2844.2006
91. Arnold HK, Sears RC. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev (2008) 27:147-58. doi:10.1007/s10555-008-9128-9
92. Jurkovicova D, Magyerkova M, Kulcsar L, Krivjanska M, Krivjansky V, Gibadulinova A, et al. miR-155 as a diagnostic and prognostic marker in hematological and solid malignancies. Neoplasma (2014) 61:241-51. doi:10.4149/neo_2014_032
93. O'Connell RM, Zhao JL, Rao DS. MicroRNA function in myeloid biology. Blood (2011) 118:2960-9. doi:10.1182/blood-2011-03-291971
94. Lee DW, Futami M, Carroll M, Feng Y, Wang Z, Fernandez M, et al. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene (2012) 31:4085-94. doi:10.1038/onc.2011.579
95. Yoon BS, Jun EK, Park G, Jun Yoo S, Moon JH, Soon Baik C, et al. Optimal suppression of protein phosphatase 2A activity is critical for maintenance of human embryonic stem cell self-renewal. Stem Cells (2010) 28:874-84. doi:10.1002/stem.412
96. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene (2002) 21:3414-21. doi:10.1038/sj.onc.1205400
97. Ren J, Jin P, Wang E, Marincola FM, Stroncek DF. MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 7:20. doi:10.1186/1479-5876-7-20
98. Feng X, Wang Z, Fillmore R, Xi Y. miR-200, a new star miRNA in human cancer. Cancer Lett (2014) 344:166-73. doi:10.1016/j.canlet.2013.11.004
99. Huang HN, Chen SY, Hwang SM, Yu CC, Su MW, Mai W, et al. miR-200c and GATA binding protein 4 regulate human embryonic stem cell renewal and differentiation. Stem Cell Res (2014) 12:338-53. doi:10.1016/j.scr.2013.11.009
100. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 123:4144-57. doi:10.1172/JCI68951
101. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature (2005) 435:828-33. doi:10.1038/nature03552
102. Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci U S A (2008) 105:19678-83. doi:10.1073/pnas.0811166106
103. Kwanhian W, Lenze D, Alles J, Motsch N, Barth S, Döll C, et al. MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. Cancer Med (2012) 1:141-55. doi:10.1002/cam4.29
104. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 368:2059-74. doi:10.1056/NEJMoa1301689
105. Finnerty JR, Wang WX, Hébert SS, Wilfred BR, Mao G, Nelson PT. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol (2010) 402:491-509. doi:10.1016/j.jmb.2010.07.051
106. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology (2009) 50:113-21. doi:10.1002/hep.22919
107. Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, et al. MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. Cancer Lett (2014) 347:65-74. doi:10.1016/j.canlet.2014.01.019
108. Ding J, Huang S, Wang Y, Tian Q, Zha R, Shi H, et al. Genome-wide screening reveals that miR-195 targets the TNF-a/NF-?B pathway by down-regulating I?B kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology (2013) 58:654-66. doi:10.1002/hep.26378
109. Díaz-Beyá M, Navarro A, Ferrer G, Díaz T, Gel B, Camós M, et al. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia (2013) 27:595-603. doi:10.1038/leu.2012.278